prohibited substance raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-10 and is reviewed periodically as new material appears.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 0.9 kDa | Depends on exact fragment sequence and counterion |
| Amino acid sequence | LKKTETQ (commonly cited) | Short actin-binding motif from thymosin beta-4 |
| Common salt form | Acetate salt | Trifluoroacetate also reported in research material |
| Reconstitution solvent | Sterile water or buffer | Gentle mixing; avoid vigorous agitation |
| Solution storage | -20 °C or lower | Aliquot to avoid repeated freeze-thaw cycles |
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Mutations or buffer conditions known to improve aggregation strongly increase the population of the beta conformer, thus suggesting this could be a conformation related to pathogenic aggregation. One theory is that the majority of alpha-synuclein aggregates are located in the presynapse as smaller deposits which causes synaptic dysfunction. Among the strategies for treating synucleinopathies are compounds that inhibit aggregation of alpha-synuclein. It has been shown that the small molecule cuminaldehyde inhibits fibrillation of alpha-synuclein. The Epstein-Barr virus has been implicated in these disorders. In rare cases of familial forms of Parkinson's disease, there is a mutation in the gene coding for alpha-synuclein. Five point mutations have been identified thus far: A53T, A30P, E46K, H50Q, and G51D; however, in total, nineteen mutations in the SNCA gene have been associated with parkinsonism: A18T, A29S, A53E, A53V, E57A, V15A, T72M, L8I, V15D, M127I, P117S, M5T, G93A, E83Q, and A30G. It has been reported that some mutations influence the initiation and amplification steps of the aggregation process. Genomic duplication and triplication of the gene appear to be a rare cause of Parkinson's disease in other lineages, although more common than point mutations. Hence certain mutations of alpha-synuclein may cause it to form amyloid-like fibrils that contribute to Parkinson's disease.
== Production == Plans to create a Nick Fury live action production were circulated as early as September 1986, but it was not until mid-May 1995 that Fox Broadcasting announced the acquisition from New World Entertainment of a Nick Fury series pilot, to be broadcast in 1996. The film was originally sold to Paramount Pictures, with Debra Hill and Lynda Obst as producers, Greg Pruss to write and Stephen Herek originally attached to direct. The teleplay was written by David S. Goyer several years before the film was made, and Goyer was not otherwise involved as he was working on the television series Sleepwalkers. Despite some misgivings within the studio, the producers cast David Hasselhoff in the lead role "to give SHIELD some recognizable star power". The production also markedly "respected and utilized the comic roots of the project", incorporating "a who's who of the Marvel spy scene" and retaining details such as Fury's eyepatch. Goyer was not enthusiastic about the casting of David Hasselhoff, but in hindsight said, "Hasselhoff turned out to be the best thing in it. He got the joke. The script was meant to be very tongue in cheek, and Hasselhoff understood that. Goyer described the film overall as "pretty mediocre". Hasselhoff was reportedly signed for five additional Nick Fury television films, which did not materialize. Shooting for the project occurred between May and June 1997 in Vancouver, British Columbia, Canada.
=== Precursor to the antioxidant glutathione === Due to the ability of thiols to undergo redox reactions, cysteine and cysteinyl residues have antioxidant properties. Its antioxidant properties are typically expressed in the tripeptide glutathione, which occurs in humans and other organisms. The systemic availability of oral glutathione (GSH) is negligible; so it must be biosynthesized from its constituent amino acids, cysteine, glycine, and glutamic acid. While glutamic acid is usually sufficient because amino acid nitrogen is recycled through glutamate as an intermediary, dietary cysteine and glycine supplementation can improve synthesis of glutathione.
== Compartmentalization and genome integration == Hypercycle theory proposed that hypercycles are not the final state of organization, and further development of more complicated systems is possible by enveloping the hypercycle in some kind of membrane. After evolution of compartments, a genome integration of the hypercycle can proceed by linking its members into a single chain, which forms a precursor of a genome. After that, the whole individualized and compartmentalized hypercycle can behave like a simple self-replicating entity. Compartmentalization provides some advantages for a system that has already established a linkage between units. Without compartments, genome integration would boost competition by limiting space and resources. Moreover, adaptive evolution requires the package of transmissible information for advantageous mutations in order not to aid less-efficient copies of the gene. The first advantage is that it maintains a high local concentration of molecules, which helps to locally increase the rate of synthesis. Secondly, it keeps the effect of mutations local, while at the same time affecting the whole compartment. This favours preservation of beneficial mutations, because it prevents them from spreading away. At the same time, harmful mutations cannot pollute the entire system if they are enclosed by the membrane. Instead, only the contaminated compartment is destroyed, without affecting other compartments. In that way, compartmentalization allows for selection for genotypic mutations.
Sources: en.wikipedia.org
nucleoplasm Also karyoplasm. All of the material enclosed within the nucleus of a cell by the nuclear envelope, analogous to the cytoplasm enclosed by the main cell membrane. Like the cytoplasm, the nucleoplasm is composed of a gel-like substance (the nucleosol) in which various organelles, nuclear proteins, and other biomolecules are suspended, including nuclear DNA in the form of chromosomes, the nucleolus, nuclear bodies, and free nucleotides.
The black desert cobra (Walterinnesia aegyptia) is a highly venomous snake species found in the Middle East. The subcutaneous LD50 for the venom of this species is 0.40 mg/kg. For comparison, the Indian cobra's (naja naja) subcutaneous LD50 is 0.80 mg/kg, while the Cape cobra's (naja nivea) subcutaneous LD50 is 0.72 mg/kg. This makes the black desert cobra a more venomous species than both. The venom is strongly neurotoxic and also has mild hemotoxic factors. Envenomation usually causes some combination of local pain, swelling, fever, general weakness, headache, & vomiting. This is not a typically aggressive snake, but it will strike and hiss loudly when provoked. It can strike at a distance of two-thirds of its body length. It does not usually spread a hood nor hold up its body up off the ground like true cobras do. Envenomation by this species should be considered a serious medical emergency. Human fatalities due to envenomation by this species have been reported.
Rocha-Méndez et al. (2026) report evidence from the study of mitochondrial genomes of European fallow deers from the Neumark-Nord sites (Germany) indicative of loss of genetic diversity of the species since the Pleistocene, recovering the studied extinct population from a single Eemian locality with as much genetic diversity as seen in extant population with a Eurasian range. Chung & Cho (2026) describe new antler remains of Elaphurus formosanus from the Pleistocene of Taiwan and support recognition of the species as distinct. Amanova, Drucker & Fontana (2026) reconstruct the ecology and habitat use of red deers from the Epigravettian sequence of Riparo Tagliente (Italy) on the basis of the study of carbon and oxygen isotopic composition of their tooth enamel, reporting evidence of a diet based on C3 plants and life in the landscape dominated by open woodland environments. Kubo, Yamazaki & Taniguchi (2026) reconstruct the diet of early to mid-Holocene sika deers from the Iyai Rockshelter Site (Japan) on the basis of the study on their tooth wear texture, reporting evidence of abrasive food in their diets and short-term temporal changes in foraging conditions. Martínez-Polanco (2026) determines diet of extant Neotropical deer (including local dietary variation within species) on the basis of the study of their tooth wear, providing reference data that can be used to determine diets of fossil deer and other small- to medium-sized ungulates.
Sources: en.wikipedia.org
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.
Reversed-phase liquid chromatography separates components and reports purity from peak area. Mass spectrometry confirms the molecular mass expected for the sequence. Additional approaches such as peptide mapping or amino acid analysis provide independent confirmation.
Reported percentages depend on the analytical method, the detection wavelength, and whether salts and water are counted. A value above ninety-five percent by chromatography does not by itself establish a correct sequence. Different suppliers also calculate purity against different reference standards.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.